🚨 ARGX: ARGENX Achieves First Operating Profitability with $1.1B in 2025, Reports $4.2B Sales & Positive Phase 3 VYVGART Data in Ocular MG

New Filing: 6-K

Ticker: ARGX | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

ARGENX SE reported its first year of operating profitability in 2025 with $1.1 billion in operating income and $4.2 billion in global product net sales, alongside positive Phase 3 results for VYVGART in ocular myasthenia gravis, supporting a planned label expansion.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC insights.